Details for New Drug Application (NDA): 060764

NDA 060764 describes NEOMYCIN AND POLYMYXIN B SULFATES AND BACITRACIN ZINC, which is a drug marketed by Bausch And Lomb, Padagis Us, and Sciegen Pharms Inc, and is included in three NDAs. It is available from two suppliers. Additional details are available on the NEOMYCIN AND POLYMYXIN B SULFATES AND BACITRACIN ZINC profile page.

The generic ingredient in NEOMYCIN AND POLYMYXIN B SULFATES AND BACITRACIN ZINC is bacitracin zinc; neomycin sulfate; polymyxin b sulfate. There are twenty-seven drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the bacitracin zinc; neomycin sulfate; polymyxin b sulfate profile page.

Summary for 060764

Tradename:	NEOMYCIN AND POLYMYXIN B SULFATES AND BACITRACIN ZINC
Applicant:	Padagis Us
Ingredient:	bacitracin zinc; neomycin sulfate; polymyxin b sulfate
Patents:	0

Pharmacology for NDA: 060764

Physiological Effect

Decreased Cell Wall Synthesis & Repair

Suppliers and Packaging for NDA: 060764

Tradename	Generic Name	Dosage	NDA	Application Type	Supplier	National Drug Code	Package Code	Package
NEOMYCIN AND POLYMYXIN B SULFATES AND BACITRACIN ZINC	bacitracin zinc; neomycin sulfate; polymyxin b sulfate	OINTMENT;OPHTHALMIC	060764	ANDA	Padagis US LLC	0574-4250	0574-4250-35	1 TUBE in 1 CARTON (0574-4250-35) / 3.5 g in 1 TUBE

Profile for product number 002

Active Rx/OTC/Discontinued:	RX	Dosage:	OINTMENT;OPHTHALMIC			Strength	400 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GM
Approval Date:	Approved Prior to Jan 1, 1982	TE:	AT	RLD:	No

Complete Access Available with Subscription